Merck KGaA Profit Beats Estimates on Cost-Cutting

May 14 (Bloomberg) -- Merck KGaA, the German maker of cancer drug Erbitux, said first-quarter profit rose on higher-than-expected savings from a reorganization program, and forecast it will achieve 2014 targets a year ahead of schedule. Mark Barton reports on Bloomberg Television's "Countdown." (Source: Bloomberg)
Kors Shares Tumble After Forecast Misses Estimates
33:59 - Bloomberg's Julie Hyman updates today's top markets news stories. She reports on “Market Makers.” (Source: Bloomberg)
  • BofA CEO Moynihan: Trading Division Faces More Cost Cuts
  • Here's What's Moving Markets Today
  • Breaking Down Tiffany's Earnings Numbers